Multi-center study reveals unique subtypes of most common...
An international collaborative study has revealed detailed new information about diffuse glioma, the most common type of tumor found...
MD Anderson joins nation’s cancer centers in endorsement of...
In response to low national vaccination rates for the human papillomavirus (HPV), The University of Texas MD Anderson Cancer Center...
Targeted Axillary Dissection of lymph nodes after...
A new procedure developed by surgeons at The University of Texas MD Anderson Cancer Center improves the accuracy of axillary staging...
Potential therapeutic targets identified for multiple sclerosis
Treatment of multiple sclerosis (MS) and other inflammatory diseases may benefit by new findings from a study that identified...
MD Anderson, AbbVie connect to advance cancer immunotherapy
The immunotherapy platform at The University of Texas MD Anderson Cancer Center and the global biopharmaceutical company AbbVie will...
New findings may enhance PARP inhibitors therapy in breast...
Findings from a new study reveal that PARP inhibitors, an emerging class of drugs being studied in cancer clinical trials, may be...
MD Anderson Applauds State of the Union Call to Cure Cancer
The University of Texas MD Anderson Cancer Center is grateful Vice President Joe Biden has inspired the creation of a national cancer...
MD Anderson and Enumeral enter into collaborative research...
The University of Texas MD Anderson Cancer Center today announced that it has entered into a collaborative research and development...
Study reveals potential therapy targets for triple-negative...
In cancer, cell signaling pathways are the critical chain of events that can either quash or quicken disease progression.
A...
MD Anderson and Kymab announce research and development strategic...
Kymab, a leading human monoclonal antibody biopharmaceutical company, and The University of Texas MD Anderson Oncology Research for...